Kestra Medical Technologies, Ltd. cash flow to debt ratio of -165.86% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kestra Medical Technologies, Ltd.'s free cash flow has decreased 19.41% from $-84.75M last year to $-101.20M, signaling decreasing performance

Kestra Medical Technologies, Ltd.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Kestra Medical Technologies, Ltd.'s debt has decreased relative to shareholder equity from 0.22 last year to 0.02 today, signaling strengthened financials

Kestra Medical Technologies, Ltd. has a net cash position, so leverage is healthy.

Kestra Medical Technologies, Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Kestra Medical Technologies, Ltd.'s profit margin has increased (-27.29%) in the last year from -190.28% to -138.36%, signaling increasing performance

Kestra Medical Technologies, Ltd.'s short-term assets of $222.36M exceed its short-term liabilities of $50.37M

Kestra Medical Technologies, Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kestra Medical Technologies, Ltd.'s return on equity of -58.76%, is lower than 15.00%, indicating bad performance

Kestra Medical Technologies, Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kestra Medical Technologies, Ltd. has insufficient public price history to evaluate earnings stability.

Kestra Medical Technologies, Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Kestra Medical Technologies, Ltd. has negative free cash flow, indicating cash burn

Kestra Medical Technologies, Ltd.'s yearly earnings has decreased 15.64% since last year from $-113.81M to $-131.61M, signaling decreasing performance

Kestra Medical Technologies, Ltd.'s yearly revenue has increased 59.04% since last year from $59.81M to $95.13M, signaling increasing performance

ROIC -43.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kestra Medical Technologies, Ltd.'s 3-year revenue CAGR of 131.88% is positive, indicating growing revenue over the past 3 years

Kestra Medical Technologies, Ltd. has insufficient public price history to evaluate revenue consistency.

Kestra Medical Technologies, Ltd. has insufficient public price history to evaluate ROE consistency.

Kestra Medical Technologies, Ltd. has insufficient data to evaluate this check.

Kestra Medical Technologies, Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kestra Medical Technologies, Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kestra Medical Technologies, Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kestra Medical Technologies, Ltd. has insufficient data to evaluate this check.

Kestra Medical Technologies, Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kestra Medical Technologies, Ltd. has a price-to-book ratio of 6.38x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Kestra Medical Technologies, Ltd. has a price-to-sales ratio of 17.40x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue